On Monday, Purple Biotech Ltd (NASDAQ:PPBT) reported the final results from the randomized Phase 2 study of its lead oncology drug, CM24, a humanized monoclonal antibody that blocks CEACAM1, in ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...
Option chain shows key data for Purple Biotech's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Purple Biotech ( (PPBT)) just unveiled an ...
16d
Purple Biotech Is Building What Could Be the Next Generation of Cancer Immunotherapy (NASDAQ: PPBT)
Cancer immunotherapy has already had its first revolution. Checkpoint inhibitors changed the treatment landscape by helping the immune system recognize when to attack. Then came a more engineered wave ...
Purple Biotech Ltd. ADR Annual cash flow by MarketWatch. View PPBT net cash flow, operating cash flow, operating expenses and cash dividends.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results